Anavex stock plunged 50% in premarket trading after European regulators issued a negative vote on its Alzheimer’s drug ...

Anavex Life Sciences Corp. (NASDAQ:AVXL) saw its stock plunge by 50% on Friday after revealing that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) delivered a ...

My personal journey proves confronting Alzheimer’s can transform lives — and that public action is essential. It is a wake-up ...

Anavex Life Sciences said European regulators informed it of a negative trend vote related to its application for its blarcamesine treatment of early Alzheimer's disease. The Committee for Medicinal ...

Anavex Life Sciences (AVXL) stock falls as the company faces a potential failure to win EU approval for its Alzheimer’s ...

Investing.com -- Anavex Life Sciences Corp. (NASDAQ:AVXL) stock plummeted 50% after the company received a negative trend vote from the European Medicines Agency’s Committee for Medicinal Products for ...

The roadmap to fighting Alzheimer’s disease is a matter of updating government policy to match the current science.

An artificial intelligence tool that can predict a patient’s health has been created by Victorian researchers, introducing a ...

A new study shows that lecanemab, an amyloid-clearing Alzheimer’s therapy, does not improve the brain’s waste-removal network ...

Dementia deaths have risen steadily over the past decade, reflecting Australia's ageing population, according to the ABS.

New data on causes of death reveals more than 17,500 people died of dementia in 2024 nationwide, according to the Australian ...

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, 'Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: ...